PPT-Detection of Mutations in EGFR in Circulating Lung-Cancer C

Colin Reisterer and Nick Swenson S Maheswaran et al The New England Journal of Medicine 2007 httpwwwallcancertreatmentscomtypesoflungcancerhtml Clinical background Nonsmall cell lung cancer NSCLC. Each year more people die of lung cancer than of colon breast and prostate canc ers combined Most lung cancers could be prevented because they are related to smoking or secondhand smoke or less often to exposure to radon or other environmental facto Nagrath. & . Sequist. et al. (2007). Journal Presentation. Brigitte Morales & Leanna Morinishi. December 8. th. , 2011. Nagrath. , S., . Sequist. , L. et al. Nature 450.7173 (2007):1235-239. Print.. carcinoma. - . new. . biomarkers. Rafal. . Dziadziuszko. Medical. . University. of Gdańsk, Poland. Molecular. . aberrations. . in . lung. . adenocarcinoma. Driving. . molecular. . events. :. Arshed A. Quyyumi, MD . Professor of Medicine . Emory Clinical Cardiovascular Research Institute (ECCRI). Emory University School of Medicine. Atlanta, GA. Grant support: . National Institutes of Health, . Cell Free Circulating . DNA in Detecting EGFR Mutations Present in Tumor . Tissue. S. Das. 1. , L. Bazhenova. 2. , V. Singh. 3. , L. Arnold. 3. , V. Alexiadis. 3. , T. Watanaskul. 3. ; . 1. Internal Medicine, Division of Hematology-Oncology, University of California San Diego, La Jolla, CA/United States of America, . TKI. s. . and . related. . treatment . strategies. Rafal . Dziadziuszko. Medical. . University. of Gdańsk, Poland. 16th European . Congress. „. Perspectives. in . Lung. Cancer. ” . Torino. On behalf of the North of England Cancer Network Lung NSSG. Dr Naomi Chamberlin, Dr Ann Ward. Aims. Overview of brief. Method. Contributing Trusts. Results. Discussion. Overview of brief. To gather data on all patients with a diagnosis of non-small cell lung cancer across the Network for whom specimens have been sent for EGFR mutation testing.. k. inase . i. nhibition. Danny Rayes . Epidermal Growth Factor Receptor. EGF + EGFR .  growth and proliferation. Mutant EGFR (no ligand) .  growth and proliferation. Inhibiting activating mutations. Lung cancer. What does this have to do with BRG1?. LOH . in chromosome 19 is frequent in NSLC tumors. BRG1 . is very frequently inactivated in lung tumors. . (as many as 1/3 of NSCLC cell lines have mutations in BRG1). This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Consequences of the Lack of Patients of color & Structural barriers to Quality. Christopher S. Lathan, M.D., M.S., M.P.H. Assistant Professor of Medicine. Faculty Director of Cancer Care Equity, Dana-Farber Cancer Institute. Dani. S. . Zander. , MD. Professor and Chair, Dept. of Pathology. Penn State College of Medicine/Penn State M.S. Hershey Medical Center, Hershey, PA. Smoking-Related Lung Diseases. Cause. Chronic obstructive lung disease (COPD): emphysema, chronic bronchitis, small airway disease. Ana Rima. Lung Cancer: Incidence and Mortality. New cases in 2013: 228,190. 40% with stage IV disease at presentation (~ 90,000). ~ 160,000 deaths in 2012, comparable to prostate, pancreas, breast, and colon cancer combined. Specificity and Universal Cancer Detection using Plasma. James G. Herman, M.D.. Jeff Wang, Ph.D.. The UPMC Hillman Cancer Center. The University of Pittsburgh. The Johns Hopkins University. Highly Prevalent Tumor Specific Methylation Defined for Lung CA.